| B. 5-year risk (%) of initiation of RRT | |||
| Observed (95% CI) | Predicted by the SHARP CKD-CVD model | Predicted by the Tangri et al model | |
| SHARP participants overall | 36.5 (35.2 to 37.8) | 34.2 | 34.3 |
| Stage 3B | 7.3 (6.0 to 8.5) | 9.1 | 7.7 |
| Stage 4 | 34.6 (32.6 to 36.6) | 29.8 | 32.0 |
| Stage 5, not on RRT | 84.0 (81.6 to 86.1) | 79.9 | 76.0 |
| CRIB participants overall | 45.1 (39.4 to 50.2) | 46.0 | 49.4 |
*Participants with baseline vascular disease, diabetes and low-density lipoprotein (LDL) cholesterol <70 or >189 mg/dL, as well as ezetimibe/simvastatin-allocated participants in SHARP were excluded from the analyses. The Pooled Cohort Equations predict the risk of the first atherosclerotic cardiovascular disease (ASCVD) event, while the first major vascular event or vascular death endpoint in SHARP and AURORA also include revascularisations and non-ASCVD vascular deaths. Therefore, the risks produced by the Pooled Cohort Equations were calibrated by a factor corresponding to the proportion of revascularisations and non-ASCVD vascular deaths in the respective group of participants.
AURORA, A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events; CKD, chronic kidney disease; CRIB, Chronic Renal Impairment in Birmingham; CVD, cardiovascular disease; LDL, low density lipoprotein; RRT, renal replacement therapy; SHARP, Study of Heart and Renal Protection.